Interactions between lipid A and serum proteins

Advances in Experimental Medicine and Biology

Volumn 667, Issue , 2009, Pages 39-51

  Andrä, Jörg ^a   Gutsmann, Thomas ^a   Müller, Mareike ^a   Schromm, Andra B ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERICIDAL PERMEABILITY INCREASING PROTEIN; CATHELICIDIN; CD14 ANTIGEN; CYTOKINE; HIGH DENSITY LIPOPROTEIN; LACTOFERRIN; LIPID A; LIPOPOLYSACCHARIDE BINDING PROTEIN; LOW DENSITY LIPOPROTEIN; PROTEIN MD 2; SERUM ALBUMIN; THROMBOPLASTIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING SITE; CELL ACTIVATION; CYTOKINE PRODUCTION; CYTOTOXICITY; ENTHALPY; GRAM NEGATIVE BACTERIUM; HUMAN; HYDROPHOBICITY; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; LIPID HYDROLYSIS; LIPID TRANSPORT; MUTATIONAL ANALYSIS; NEUTROPHIL; NONHUMAN; PHASE TRANSITION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN DOMAIN; PROTEIN STABILITY; SEPTIC SHOCK; STOICHIOMETRY;

AMINO ACID SEQUENCE; BLOOD PROTEINS; HUMANS; IMMUNOGLOBULINS; LIPID A; MOLECULAR SEQUENCE DATA;

EID: 77952533715     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-1603-7_4     Document Type: Article

References (140)

1. Riecschel ET, Mamar U, Hamann L et al. Bacterial endotoxins as inducers of septic shock. Novo Acta Leopoldina 1999; 307:93-122.
2. Alexander C, Rietschel ET. Bactcrial lipopolysaccharides and innate immunity. J Endotoxin Res 2001 ; 7:167-202.
3. Frey EA, Miller DS, Jahr TG et al, Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med 1992; 176:1665-1671.
4. Schumann RR, Leong SR, FlaggsGW et al. Structure and function of lipopolysaccharide binding protein Science 1990; 249:1429-1431. (Pubitemid 120034117)
5. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, MathisonJC. CDI4, a recepto r for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249:1431-1433.
6. Polrorak A, He X, Smirnova 1 et al. Defective LPS signaling in C3H/HeJ and C57BL/I0ScCr mice: Mutations in Tlr4 gene. Science 1998; 282 :2085-2088. (Pubitemid 29001265)
7. Qureshi ST, Lariviere L, Leveque G et al Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med 1999; 189:615-625. (Pubitemid 29193362)
8. Hoshino K, Takeuchi O, Kawai T et al. Cutting edge: Toll-like receptor 4 (TLR4)-de6cient mice are hyporesponsive to lipopolysaccharide : Evidence for TLR4 as the Lps gene product. J Immunol 1999; 162:3749-3752. (Pubitemid 29314747)
9. Shimazu R, Akashi S, Ogata H et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999; 189:1777-1782. (Pubitemid 29272694)
10. Nagai Y, Akashi S, Nagafuku M et al. Essential role ofMD-2 in LPS responsiveness and TLR4 distribution Nat Irnmunol 2002; 3:667-672. (Pubitemid 34752476)
11. Ramadori G. Meyer zum Buschenfelde KH. Tobias PS et al. Biosynthesis of lipopolysaccharide-binding protein in rabbit hepatocytes, Pathobiology 1990; 58:89-94. (Pubitemid 20160832)
12. Wurfel MM. Monks BG, Ingalls RR et al. Targeted deletion of the lipopolysaccharide (LPS)-binding protein gene leads to profound suppression of LPS responses ex vivo. whereas in vivo responses remain intact J Exp Med 1997; 186:2051-2056. (Pubitemid 28013690)
13. Jack RS, Fan X, Bemheiden M et al. Lipopolysaccharide-binding protein is required to combat a murine gram-negative bacterial infection. Nature 1997; 389:742-745. (Pubitemid 27458962)
14. Gallay P. Heumann D. Le Roy D et al. Lipopolysaccharide-binding protein as a major plasma protein responsible for endoroxemic shock. Proc Natl Acad Sci USA. 1993; 90:9935-9938. (Pubitemid 23328225)
15. Tobias PS. Soldau K. Ulevitch RJ. Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein. J Biol Chern 1989; 264: 10867-10871. (Pubitemid 19161662)
16. Gazzano-Santoro H. Meszaros K, Birr C et al. Competition between rBPI23, a recombinant fragment ofbactericidallpermeability-increasing protein. and lipopolysaccharide (LPS)-binding protein for binding to LPS and gram-negative bacteria. Infect Immun 1994; 62:1185-1191.
17. Theofan G. Horwitz AH , Williams RE et al. An amino-terminal fragment of human lipopolysaccharide- binding protein retains lipid A binding but not CDl4-stimulatory activity. J Immunol 1994; 152:3623-3629 (Pubitemid 24098060)
18. Han J. Mathison JC. Ulevirch RJ et al. Lipopolysaccharide (LPS) binding protein , truncated at Ile-197, binds LPS but does not transfer LPS to CDI4. J Biol Chern 1994; 269:8172-8175. (Pubitemid 24200228)
19. Schromm AB. Brandenburg K. Rierschel ET et al. Lipopolysaccharide-binding protein mediates CDl4-independent intercalation oflipopolysaccharide into phospholipid membranes. FEBS Lett 1996; 399:267-271. (Pubitemid 26426864)
20. Schromm AB. Brandenburg K, Loppnow H et al. The charge of endotoxin molecules influences their conformation and IL-6-inducing capacity. J Immunol1998; 161:5464-5471. (Pubitemid 28519109)
21. Schromm AB. Brandenburg K, Loppnow H et al. Biological activities oflipopolysaccharides are determined by the shape of their lipid A portion. Eur J Biochem 2000; 267:2008-2013. (Pubitemid 30185287)
22. Gutsmann T. Schromm AB, Koch MHJ et al. Lipopolysaccharide-binding protein-mediated interaction of lipid A from different origin with phospholipid membranes. Phys Chern Chern Phys 2000; 2:4521-4528
23. Viriyakosol S, Kirkland TN. A region of human CD14 required for lipopolysaccharide binding. J Biol Chern 1995; 270:361-368.
24. McGinley MD , Narhi LO. Kelley MJ et al. CDI4: Physical properties and identification of an exposed site that is protected by lipopolysaccharide. J Biol Chern 1995; 270:5213-5218.
25. Juan TS. Kelley MJ. Johnson DA et al. Soluble CD14 truncated at amino acid 152 binds lipopolysaccharide (LPS) and enables cellular response to LPS. J Biol Chern 1995; 270:1382-1387.
26. Juan TS. Hailman E, Kelley MJ et al. Identification of a lipopolysaccharide binding domain in CD 14 between amino acids 57 and 64. J Biol Chern 1995; 270:5219-5224.
27. Juan TS, Hailman E. Kelley MJ et al. Identification of a domain in soluble CD14 essential for lipopolysaccharide (LPS) signaling but not LPS binding J Biol Chern 1995; 270:17237-17242
28. Viriyakosol S. Kirkland TN. The N-terminal half of membrane CD14 is a functional cellular lipopolysaccharide receptor. Infect Immun. 1996; 64:653-656. (Pubitemid 26032843)
29. Stelter F. Bernheiden M. Menzel Ret al. Mutation of amino acids 39-44 of human CD14 abrogates binding of lipopolysaccharide and Escherichia coli. Eur J Biochem 1997; 243:100-109. (Pubitemid 27060390)
30. Cunningham MD , Shapiro RA. Seachord C et al. CD14 employs hydrophilic regions to 'capture' lipopolysaccharides. J Immunol 2000; 164:3255-3263. (Pubitemid 30148989)
31. Kim JI, Lee CJ. Jin MS et al. Crystal structure of CD14 and its implications for lipopolysaccharide signaling. J Biol Chern 2005; 280:11347-11351.
32. Grunwald U, Kruger C. Schutt C. Endotoxin-neutralizing capacity of soluble CD 14 is a highly conserved specific function Circ Shock 1993; 39:220-225. (Pubitemid 23086258)
33. Haziot A. Rong GW; Bazil V et al. Recombinant soluble CD14 inhibits LPS-induced tumor necrosis factor-alpha production by cells in whole blood. J Immunol 1994; 152:5868-5876 (Pubitemid 24174167)
34. Kitchens RL. Thompson PA. Viriyakosol S et al. Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins. J Clin Invest 2001; 108:485-493. (Pubitemid 32730795)
35. Gutsmann T. Miiller M, Carroll SF et al. Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-induced activation of mononuclear cells. Infect Immun 2001; 69:6942-6950 (Pubitemid 32995454)
36. Zweigner J, Gramm HJ. Singer OC et al. High concentrations of lipopol ysaccharide-binding protein in serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes. Blood 2001; 98:3800-3808.
37. Hamann L, Alexander C, Stamme C et al, Acute-phase concentrations of lipopolysaccharide (LPS)-binding protein inhibit innate immune cell aerivation by different LPS chemorypes via different mechanisms. Infect Immun 2005; 73:193-200. (Pubitemid 40041109)
38. Schromm AB. Lien E. Henneke P et al.Molecular genetic analysisof an endotoxin nonresponder mutant cell line: A point mutation in a conserved region of MD-2 abolishes endotoxin-induced signaling. J Exp Med 2001; 194:79-88. (Pubitemid 32660439)
39. Visintin A, Mazzoni A. Spitzer JA et al. Secreted MD-2 is a large polymeric protein that efficiently confers lipopolysaccharide sensitivity to Toll-like receptor 4. Proc Natl Acad Sci USA. 2001; 98:12156-12161. (Pubitemid 32959843)
40. Kennedy MN, Mullen GE. Leifer CA et al, A complex of soluble MD-2 and lipopolysaccharide serves as an activating ligand for Toll-like receptor 4. J Biol Chern 2004; 279:34698-34704. (Pubitemid 39318100)
41. Viriyakosol S. Tobias PS. Kitchens RL et al. MD-2 binds to bacterial lipopolysaccharide. J Biol Chern 2001; 276:38044-38051.
42. Re F, Strominger JL. Monomeric recombinant MD-2 binds toll-like receptor 4 tightly and confers lipopolysaccharide responsiveness. J Biol Chern 2002; 277:23427-23432. (Pubitemid 34952175)
43. Pugin J. Stern-Voeffray S. Daubeuf B et al. Soluble MD -2 activity in plasma from patients with severe sepsis and septic shock. Blood 2004; 104:4071-4079. (Pubitemid 39620158)
44. Visintin A. Halmen KA, Latz E et al. Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor. MD-2 J Immunol 2005; 175:6465-6472. (Pubitemid 41598888)
45. Poltorak A. Ricciardi-Castagnoli P. Citterio S et al. Physical contact between lipopolysaccharide and toll-like receptor 4 revealed by genetic complementation. Proc Natl Acad Sci USA. 2000; 97:2163-2167 (Pubitemid 30134039)
46. Lien E. Means TK. Heine H et al. Toll-like recepror 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest 2000; 105:497-504. (Pubitemid 30127250)
47. Akashi S. Nagai Y, Ogara H et al, Human MD -2 confers on mouse Toll-like recepror 4 species-specific lipopolysaccharide recognition Int Immunol 2001; 13:1595-1599. (Pubitemid 33133886)
48. Muroi M. Tanamoto K. Structural regions of MD-2 that determine the agonist-antagon ist activity of lipid IVa. J Biol Chern 2006; 281:5484-5491. (Pubitemid 43847643)
49. Viriyakosol S. Tobias PS, Kirkland TN. Mutational analysis of membrane and soluble forms of human MD -2. J Biol Chern 2006; 281:11955-11964. (Pubitemid 43855459)
50. Galanos C, Freudenberg MA. Jay F et al. Immunogenic properties of lipid A. Rev Infect Dis 1984; 6:546-552.
51. Brade L. Brandenburg K. Kuhn HM et al. The immunogenicity and antigenicity oflipid A are influenced by its physicochemical state and environment Infect Immun 1987; 55:2636-2644. (Pubitemid 17154501)
52. Brade L, Holst O. Brade H An artificial glycoconjugate containing the bisphosphorylated glucosamine disaccharide backbone of lipid A binds lipid A monoclonal antibodies. Infect Immun 1993; 61:4514-4517 (Pubitemid 23298622)
53. Brade L, Engcl R, Christ WJ et al. A nonsubstituted primary hydroxyl group in position 6' of free lipid A is required for binding of lipid A monoclonal antibodies. Infect Imrnun 1997; 65:3961-3965 (Pubitemid 27398169)
54. Galanos C, Rietschel ET, Liideritz 0 et al. Biological activities of lipid A cornplexed with bovine-serum albumin Eur J Biochem 1972; 31:230-233.
55. Rierschel ET. Kim YB, Watson DW et al. Pyrogenicity and immunogen icity of lipid A complexed with bovine serum albumin or human serum albumin. Infect Immun Aug 1973; 8:173-177.
56. Elsbach P, Weiss J. Doerfler M et al. The bactericidal/permeability increasing protein of neutrophils is a potent antibacterial and anti-endotoxin agent in vitro and in vivo. Prog Clin Biol Res 1994; 388:41-51.
57. Zhang G. Mann D. Tsai C. Neutralization of endotoxin in vitro and in vivo by a human laccoferrin-derived peptide. Infect Immun 1999; 67:1353-1358. (Pubitemid 29108516)
58. David SA. Balaram P. Machan VI. Characterization of the interaction of lipid A and lipopolysaccharide with human serum albumin : Implications for an endotoxin carrier function for albumin. J Endotoxin Res 1995; 2:99-106.
59. He XM , Carter DC. Atomic structure and chemistry of human serum albumin. Nature 1992 ; 358:209-215.
60. Morrison DC, Jacobs DM. Binding of polymyxin B to the lipid A portion of bacterial Iipopolysaccharides. Immunochem istry 1976; 13:813-818.
61. Jurgens G. Miiller M. Garidel P et al. Investigation into the interaction of recombinant human serum albumin with Re!ipopolysaccharide and lipid A. J Endotox in Res 2002; 8:115-126. (Pubitemid 34546188)
62. Gioannini TL. Zhang D. Teghanemt A et al. An essential role for albumin in the interaction of endotoxin with lipopolysaccharide-binding protein and sCD 14 and resultant cell activation. J Biol Chern 2002 ; 277:47818-47825. (Pubitemid 36159308)
63. Ginsberg HN. Lipoprotein physiology. Endocrinol Merab Clin North Am 1998; 27:503-519. (Pubitemid 28446945)
64. Van Amersfoort ES. Van Berkel TJ. Kuiper J. Receptors. mediators. and mechanisms involved in bacterial sepsis and septic shock Clin Microbiol Rev 2003; 16:379-414. (Pubitemid 36871313)
65. Feingold KR Funk JL Moser AH et al. Role for circulating lipoproteins in protection from endotoxin toxicity. Infect Immun 1995; 63:2041-2046.
66. Parker TS. Levine DM ChangJC et al. Reconstituted high-density lipoprotein neutralizes gram-negative bacteriallipopolysaccharides in human whole blood Infect Immun 1995; 63:253-258.
67. Baumberger C. Ulevitch RJ. Dayer JM Modulation of endotoxic activity of lipopolysaccharide by high-density lipoprotein. Parhobiology 1991; 59:378-383.
68. Calabresi L. Franceschini G. Sirtori CR et al. Inhibition of VCAM-l expression in endothelial cells by reconstituted high density lipoproteins. Biochem Biophys Res Commun 1997; 238:61-65 (Pubitemid 27453274)
69. Casas AT. Hubsch AP. Rogers BC et al. Reconstituted high-density lipoprotein reduces LPS-stimulated TNFu. J Surg Res 1995; 59:544-552.
70. Munford RS. Dietschy JM Effects of specific ant ibodies. hormones. and lipoproteins on bacterial lipopolysaccharides injected into the rat. J Infect Dis Jul 1985; 152:177-184. (Pubitemid 15038850)
71. Flegel WA. Wolpl A. Mannel DN et al. Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins. Infect Immun 1989; 57:2237-2245 (Pubitemid 19186908)
72. Weinstock C, Ullrich H, Hohe Ret al. Low density lipoproteins inh ibir endotoxin activation of monocytes. Arterioscler Thromb. 1992; 12:341-347.
73. Morel DW; DiCorieto PE, Chisolm GM Modulation of endotoxin-induced endothelial cell toxicity by low density lipoprotein. Lab Invest 1986; 55:419-426. (Pubitemid 17189288)
74. Emancipator K, Csako G. Elin RJ. In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins. Infect Immun 1992; 60 :596-601.
75. Harris HW; Rockey DC, Chau P. Chylomicrons alter the hepatic distribution and cellular response to endotoxin in rats. Hepatology 1998; 27:1341-1348. (Pubitemid 28227862)
76. Kitchens RL. Thompson PA. Munford RS et al. Acute inflammation and infection mainta in circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteins. J Lipid Res 2003 ; 44 :2339-2348. (Pubitemid 38082492)
77. Sprong T. Netea MG van der Ley P et al. Human lipoproteins have divergent neutralizing effects on E. coli LPS, N. meningitidis LPS. and complete Gram-negative bacteria. J Lipid Res 2004 ; 45 :742-749. (Pubitemid 38405681)
78. Netea MG. van Deuren M. Kullberg BJ et al. Does the shape of lipid A determ ine the inte raction of LPS with Toll-like receptors ? Trends Immunol 2002 ; 23 :135-139. (Pubitemid 34178295)
79. Seydel U. Hawkins L. Schromm A et al. The generalized endotoxic pr inciple. Eur J Immunol 2003 ; 33:1586-1592
80. Levine DM , Parker TS Donnelly TM et al. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U.S.A. 1993; 90:12040-12044. (Pubitemid 24008776)
81. Brandenburg K. Jurgens G. Andra J et al. Biophysical characterization of the interaction of high-density lipoprotein (HDL) with endoroxins, Eur J Biochem 2002 ; 269:5972-5981. (Pubitemid 35425595)
82. Loppnow H Libby P. Freudenberg M et al. Cyrokine induction by lipopolysaccharide (LPS) corresponds to lethal toxicity and is inhibited by nontoxic Rhodobacrer capsularus LPS. Infect Immun 1990; 58:3743-3750. (Pubitemid 20353378)
83. Christ WJ. Asano O. Robidoux AL et al. E5531, a pure endotoxin antagonist of high potency. Science 1995; 268 :80-83
84. Rose JR. Mullarkey MA, Christ WJ et al. Consequences of interaction of a lipophilic endotoxin antagon ist with plasma lipoproteins. Antimicrob Agents Chemother 2000 ; 44 :504-510. (Pubitemid 30117933)
85. Wasan KM. Strobel FW, Parrott SC et al. Lipoprotein distribution of a novel endotoxin antagonist. E5531. in plasma from human subjects with various lipid levels. Antimicrob Agents Chemother 1999; 43 :2562-2564. (Pubitemid 29471249)
86. Wasan KM, Sivak O Cote RA et al. Association of the endotoxin antagonist E5564 with high-d ensity lipoproteins in vitro : Dependence on low-density and triglyceride-rich lipoprotein concentrations. Antimicrob Agents Chernother 2003 ; 47 :2796-2803. (Pubitemid 37040250)
87. Rossignol DP, Wasan KM, Choo E et al. Safety, pharmacokinetics. pharmacodynamics and plasma lipo - protein distr ibution of eritoran (E5564) during continuous int ravenous infusion into healthy volunteers Antimicrob Agents Chernother 2004 ; 48 :3233-3240.
88. Ma J. Liao XL, Lou B et al. Role of apolipoprotein A-I in protecting against endotoxin toxicity. Acta Biochim Bioph ys Sin (Shanghai) 2004 ; 36:419-424. (Pubitemid 39091573)
89. Gupta H. Dai L. Datta G et al. Inhibition of lipopol ysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide. Circ Res 2005 ; 97:236-243. (Pubitemid 41105449)
90. Mueller M. Lindner B. Kusumoto S et al. Aggregates are the biologically active un its of endotoxin. J Biol Chem 2004; 279:26307-26313. (Pubitemid 38798780)
91. Freudenberg MA, Bog-Hansen TC, Back U et al. Interaction of lipopolysaccharides with plasma high-density lipoprotein in rats. Infect Immun 1980; 28:373-380. (Pubitemid 10102069)
92. Munford RS. Andersen JM. Dietschy JM. Sites of tissue binding and uptake in vivo of bacterial lipopolysaccharide-high density lipoprotein complexes: Studies in the rat and squirrel monkey. J Clin Invest 1981; 68:1503-1513. (Pubitemid 12194406)
93. Freudenberg MA. Galanos C. Bacrerial lipopolysaccharides: Structure metabolism and mechanisms of action Int Rev Immunol1990; 6:207-221.
94. Read TE. Harris HW; Grunfdd C et al. Chylomicrons enhance endotoxin excretion in bile. Infect Immun 1993; 61:3496-3502 (Pubitemid 23223444)
95. Brandenburg K. Jiirgens G. Muller M et al. Biophysical characterization of lipopolysaccharide and lipid A inactivation by lacroferrin. Biol Chern 2001; 382:15-25.
96. Andra J. Lohner K. Blondelle SE et al. Enhancement of endotoxin neutral ization by coupling of a C12-alkyl chain to a lacroferricin-derivcd peptide. Biochern J 2005; 385:135-143.
97. Appelmelk BJ. An YQ, Geerts M et al. Lactoferrin is a lipid A-binding protein Infect Immun Jun 1994; 62:2628-2632. (Pubitemid 24157102)
98. Elass-Rochard E. Roseanu A. Legrand D et al, Lacroferrin- Iipopolysaccharide int eraction: Involvement of the 28-34 loop region of human lactoferrin in the high-affinity binding to Escherichia coli 055B5 lipopol ysaccharide. Biochem J 1995; 312:839-845. (Pubitemid 26005997)
99. van Berkel PH Geerts ME. van Veen HA et al. N-terminal stretch Arg2. Atg3. Atg4 and AtgS of human lacroferrin is essential for binding to heparin. bacterial lipopolysaccharide. human lysozyme and DNA. Biochem J 1997; 328:145-151. (Pubitemid 27499451)
100. Majerle A. Kidric J. jerala R. Enhancement of antibacterial and lipopolysaccharide binding activities of a human lacroferrin peptide fragment by the addition of acyl chain. J Antimicrob Chernother. 2003; 51:1159-1165. (Pubitemid 36622072)
101. Brandenburg K. Koch MH. Seydel U. Biophysical characterization of lysozyme binding to LPS Re and lipid A. Eur J Biochern 1998; 258:686-695. (Pubitemid 28557934)
102. Andra J, Koch MHJ. Bartels Ret al. Biophysicalcharacterization of the endotoxin inactivation by NK-2. an antimicrobial peptide derived from mammalian NK-Lysin. Antimicrob Agents Chemother 2004; 48 :1593-1599. (Pubitemid 38544364)
103. Andra J. Garidd P. Majerle A et al. Biophysicalcharacterization of the interaction of Limulus polyphemus endotoxin neutralizing protein (ENP) with lipopolysaccharide. Eur J Biochem 2004; 271:2037-2046. (Pubitemid 38657356)
104. Brandenburg K. Andra J. Muller M et al. Physicochemical properties of bacterial glycopolymers. Carbohydr Res 2003; 338:2477-2489.
105. Elsbach P. The bactericidal/permeability-increasing protein (BPI) in antibacterial host defense. J Leukoc Biol 1998; 64: 14-18. (Pubitemid 28304668)
106. Tobias PS. Mathison JC Ulevitch RJ. A family of lipopolysaccharide binding proteins involved in responses to gram-negative sepsis. J Biol Chern 1988: 263:13479-13481.
107. Dentener MA Von Asmurh EJ. Francot GJ et al. Antagon istic effects of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein on lipopolysaccharide-induced cytokine release by mononuclear phagocyres, Competition for binding to lipopol ysaccharide. J Immunol 1993; 151:4258-4265. (Pubitemid 23298759)
108. Heumann D. Gallay P. Barras C et al. Control of lipopolysaccharide (LPS) bind ing and LPS-induced tumor necrosis factor secretion in human peripheral blood monoc ytes. J Immunol 1992; 148:3505-3512.
109. Gutsmann T. Haberer N. Carroll SF et al. Interaction between lipopolysaccharide (LPS). LPS-binding protein (LBP). and planar membranes. Biol Chern 2001; 382:425-434 (Pubitemid 32372486)
110. Roes S. Mumm F, Seydel U et al, Localization of the lipopolysaccharide- binding protein in phospholip id membranes by atomic force microscopy. J Biol Chern 2006; 281:2757-2763. (Pubitemid 43845739)
111. Bazil V. Horejsi V, Baudys M et al. Biochemical characterization of a soluble form of the 53-kDa monocyte surface antigen. Eur. J. Immunol. 1986; 16:1583-1589. (Pubitemid 17025700)
112. Larrick JW; Hirata M. Zheng H et al. A novel granulocyte-derived peptide with lipopolysaccharideneutraliz ing activity. J Immunol 1994; 152:231-240.
113. Wurfd MM. Kunitake ST. Lichenstein H et al. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med 1994; 180:1025-1035. (Pubitemid 24256615)
114. Beamer LJ. Carroll SF, Eisenberg D. Crystal structure of human BPI and two bound phospholip ids at 2.4 angstrom resolution. Science. 1997; 276:1861-1864.
115. Beamer LJ. Carroll SF. Eisenberg D. The BPI/LBP family of proteins : A structural analysis of conserved regions. Protein Sci 1998; 7:906-914. (Pubitemid 28216532)
116. Tobias PS. Soldau K. Iovine NM et al, Lipopolysaccharide (LPS)-binding proteins BPI and LBP form different types of complexes with LPS. J Biol Chern 1997; 272:18682-18685. (Pubitemid 27318211)
117. Ooi CEO WeissJ. Elsbach P et al. A 25-kDa NH2-terminal fragment carries all the antibacterial activities of the human neutrophil 60-kD a bactericidal/permeability-increasing protein. J Biol Chern 1987; 262 :14891-14894. (Pubitemid 17160164)
118. WeissJ. Elsbach P, Shu C et al. Human bactericidallpermeability- increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. J Clin Invest 1992; 90:1122-11230.
119. Zanetti M. Gennaro R. Romeo D. Cathelicidins: A novel protein family with a common pro region and a variable C-terminal antimicrobial domain FEBS Leu 1995: 374:1-5.
120. Cowland JB. Johnsen AH. Borregaard N. hCAP-18, a carhelin/pro-bactenecin- like protein of human neutrophil specific granules. FEBS Lett 1995; 368: 173-176.
121. MaimJ. Sorensen O. Persson T et al. The human cationic antimicrobial protein (hCAP-18) is expressed in the epithelium of human epididymis. is present in seminal plasma at high concentrations, and is attached to spermatozoa. Infect Immun 2000; 68:4297-4302. (Pubitemid 30434586)
122. Frohm M. Gunne H. Bergman AC et al. Biochemical and antibacterial analysis of human wound and blister fluid. Eur J Biochem 1996; 237:86-92. (Pubitemid 26110276)
123. Agerberrh B. GrunewaldJ. Casranos-Velez E et al. Antibacterial components in bronchoalveolar lavagefluid from healthy individuals and sarcoidosis patients. AmJ Respir Crit Care Med 1999; 160:283-290. (Pubitemid 29326101)
124. JohanssonJ. Gudmundsson GH Rottenberg ME et al. Conformation-dependent antibacterial activity of the naturally occuring peptide LL-37. J Biol Chern 1998; 273:3718-3724. (Pubitemid 28109800)
125. Sorensen O. Bratt T. Johnsen AH et al. The human antibacterial cathelicidin, hCAP -18, is bound to lipoproteins in plasma. J Biol Chern 1999; 274:22445-22451.
126. Wang Y. Agerberrh B. Lothgren A et al. Apolipoprotein A-I binds and inhibits the human antibacterial/ cytotoxic peptide LL-37. J Biol Chern 1998; 273:33115-33118. (Pubitemid 29005678)
127. Hirata M. ZhongJ. Wright SC. Larrick JW Structure and functions of endotoxin -binding pepcides derived from CAPI8. Prog Clin Biol Res 1995; 392:317-326.
128. Travis SM, Anderson NN. Forsyth WR et al. Bactericidal activity of mammalian cathelicidin-derived peptides, Infect Immun 2000; 68:2748-2755. (Pubitemid 30253851)
129. Chen C Brock R. Luh F et al. The solution structure of the active domain of CAPI8-a lipopolysaccharide binding protein from rabbit leukocytes. FEBS Lett 1995; 370:46-52.
130. Turner J, Cho Y. Dinh NN et al. Activities of LL-37. a cathelin-associated antimicrobial peptide of human neurrophils, Antimicrob Agents Chemorher 1998; 42:2206-2214 (Pubitemid 28420351)
131. Oren Z. Lerman JC. Gudmundsson GH et al. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: Relevance to the molecular basis for its non cell-selective activity. Biochem J 1999: 341:501-513. (Pubitemid 29389178)
132. Hirata M. Shimomura Y. Yoshida M et al. Endotoxin-binding synthet ic peprides with endotoxin-neutralizing antibacterial and anticoagulant activities. Prog Clin Biol Res 1994; 388:147-159.
133. Vander Meer TJ. Menconi MJ. ZhuangJ et al. Protective effects of a novel 32-amino acid C -terminal fragment of CAP18 in endotoxemic pigs. Surgery. 1995: 117:656-662.
134. Kirikae T. Hirata M. Yamasu H et al. Protective effects of a human 18-kilodalron cationic antimicrobial protein (CAPI 8)-derived peptide against murine endotoxernla. Infect Immun 1998; 66:1861-1868 (Pubitemid 28194075)
135. Nagaoka I, Hirota S. Niyonsaba F et al. Cathelicidin family of antibacterial peptides CAP18 and CAPll inhibit the expression ofTNF-alpha by blocking the binding ofLPS to CDI4(+) cells. J Immunol 2001; 167:3329-3338. (Pubitemid 32852575)
136. Nagaoka I, Hirota S, Niyonsaba F et al. Augmentation of the lipopolysaccharide-neutralizing activities of human cathelicidin CAP 18/LL -37-derived antimicrobial peprides by replacement with hydrophobic and cationic amino acid residues. Clin Diagn Lab Immunol 2002: 9:972-982. (Pubitemid 34988462)
137. Ciornei CD, Sigurdardonir T, Schrnidrchen A et al. Antimicrobial and chernoarrracrant activity. lipopolysaccharide neutralization. cyrotoxiciry, and inhibition by serum of analogs of human cathelicidin LL-37. Antimicrob Agents Chernorher 2005; 49:2845-2850. (Pubitemid 40917601)
138. Nell MJ, Tjabringa GS. Wafelman AR et al. Development of novel LL-37 derived antimicrobial peptides with LPS and LTA neutralizing and antimicrobial activities for therapeutic application. Peptides 2006; 27:649-660.
139. Gursmann T, Hagge SO. LarrickJW et al. Interaction of CAP IS-derived peprides with membranes made from endotoxins or phospholipids. Biophys J 2001; 80:2935-2945. (Pubitemid 32521665)
140. Gursmann T. Fix M. Larrick JW et al. Mechanisms of action of rabbit CAPI8 on monolayers and liposornes made from endotoxins or phospholipids. J Membr Biol 2000; 176:223-236. (Pubitemid 30659953)